BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 ...

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...

Post the presentation at the 2025 JPMorgan Healthcare Conference by BridgeBio (BBIO), JPMorgan analyst Anupam Rama says the firm was “VERY encouraged” by initial Attruby metrics and notes that there ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

BridgeBio Pharma's fair value estimate has nudged higher to roughly $84.65 per share, as analysts bake in slightly stronger revenue growth assumptions of about 80.8% driven by better than expected ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. Attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby is prescribed for adults to treat ATTR-CM. To ...